On January 18, Thalys Medical Technology Group Corporation(603716) announced that the covid-19 virus antigen detection kit developed by the company has obtained EU CE certification and can be sold in the EU market. However, the product has not yet been sold in the EU, which has no significant impact on the company’s performance.
According to the announcement, Thalys Medical Technology Group Corporation(603716) shares have deviated by more than 20% from the closing price for three consecutive trading days since January 14, January 17 and January 18, 2022, belonging to abnormal fluctuations in stock trading.
Through self inspection, saihai technology, the controlling shareholder of the company, is preparing to reduce its Thalys Medical Technology Group Corporation(603716) shares through agreement transfer out of consideration of introducing strategic investors and improving the corporate governance structure. At present, it is still in the negotiation stage, and there is still great uncertainty in related matters.
In addition, the company pointed out that its independently developed covid-19 virus antigen detection kit has obtained EU CE certification and can be sold in the EU market. However, the above product certification is not exclusive to the company. There are many similar products or other detection products in the market, and the company’s product has not been sold in the EU at present, which has no significant impact on the company’s performance.
Thalys Medical Technology Group Corporation(603716) said that in addition, no major events that had a significant impact on the company’s share price, no media reports or market rumors that needed clarification or response, and no other hot concept matters were involved.
It is worth noting that in January 17th, Thalys Medical Technology Group Corporation(603716) responded to investors’ questions on the interactive platform, saying that the company New Coronavirus antigen detection kit was preparing for the emergency application authorization of the US FDA. Affected by this, from 14:40 on January 17, the company’s share price rose rapidly by 10% limit and closed at 19.01 yuan / share in late trading. Ten minutes after the opening of early trading on January 18, Thalys Medical Technology Group Corporation(603716) continued to rise the limit to close at 20.91 yuan / share.
